The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://saulduwi120762.bloguerosa.com/37580015/retatrutide-vs-tirzepatide-a-comparative-analysis